Repac, or Rap guanine nucleotide exchange factor 5, is a protein that is involved in a variety of cellular processes, including the regulation of GTPases like Rap1 and Rap2. These GTPases, in turn, are key players in multiple signaling pathways that control cell growth, differentiation, and intracellular signaling. Activated Rap GTPases can trigger downstream signaling cascades involving the MAPK/ERK and PI3K/Akt pathways. The MAPK/ERK pathway is well-known for its role in regulating cell growth and differentiation. Activation of this pathway can lead to the phosphorylation and activation of various transcription factors that ultimately promote cell cycle progression and cellular differentiation. Similarly, the PI3K/Akt pathway is involved in regulating cell survival, metabolism, and growth. By acting as a regulatory switch for Rap GTPases, Repac can indirectly influence these essential cellular functions. Given the importance of these pathways, compounds capable of inhibiting Repac are an area of interest in biochemical research. The class of Repac Inhibitors consists of molecules that can effectively inhibit the guanine nucleotide exchange activity of Repac, thereby affecting the activation state of its target GTPases.
The chemical characteristics Repac Inhibitors are diverse, reflecting the structural and functional complexities of the protein itself and its interactions with other cellular components. Some inhibitors focus on obstructing the protein-protein interactions between Repac and its target GTPases, while others aim to disrupt the protein's overall structure, rendering it inactive. Given the role of Repac in cellular signaling, such inhibitors are scrutinized for their specificity and selectivity, to ensure that they target Repac without significantly affecting other proteins or pathways. This involves rigorous biochemical assays, structural biology studies, and computational modeling to understand the interaction dynamics between the inhibitors and Repac.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
EHT 1864 might inhibit REPAC by locking Rap GTPases in an inactive state, making them unavailable for activation by REPAC. | ||||||
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $61.00 $82.00 | 15 | |
Farnesyl thiosalicylic acid (Salirasib) could bind to the Ras-binding domain of REPAC, inhibiting its interaction with Rap GTPases. | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
ZCL278 might selectively inhibit REPAC's activity toward Rap2, disrupting its role in activating this particular GTPase. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A could disrupt the Golgi apparatus, potentially affecting REPAC's cellular localization and therefore its activity. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 inhibits cytohesins, which are similar in function to REPAC; it could potentially have an off-target effect on REPAC. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Lonafarnib, a farnesyltransferase inhibitor, might inhibit REPAC indirectly by affecting Rap GTPase prenylation and localization. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A inhibits Ras farnesyltransferase and could affect the membrane localization of Rap GTPases, thereby affecting REPAC's ability to activate them. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
GGTI 298 inhibits geranylgeranyltransferase and could affect the membrane association of Rap GTPases, which in turn could affect REPAC's activity. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Tipifarnib is another farnesyltransferase inhibitor that could affect the membrane localization of Rap GTPases, potentially inhibiting REPAC's ability to activate them. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases and could potentially have off-target effects on REPAC's ability to activate Rap GTPases. | ||||||